The blood-brain barrier, chemokines and multiple sclerosis

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 2, 2011, Pages 220-230

  Holman, David W ^a   Klein, Robyn S ^a   Ransohoff, Richard M ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Blood brain barrier; Chemokine; Inflammation; Leukocyte

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; SECONDARY LYMPHOID TISSUE CHEMOKINE;

ANATOMICAL VARIATION; BLOOD BRAIN BARRIER; CELL CYCLE ARREST; CELL SURFACE; ENDOTHELIUM CELL; HUMAN; INNATE IMMUNITY; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; LYMPHOID TISSUE; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NONHUMAN; PARENCHYMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; VENULE;

ANIMALS; BLOOD-BRAIN BARRIER; CELL MOVEMENT; CHEMOKINES; ENDOTHELIUM; HUMANS; IMMUNITY, INNATE; LEUKOCYTES; LYMPHOID TISSUE; MODELS, IMMUNOLOGICAL; MODELS, NEUROLOGICAL; MULTIPLE SCLEROSIS; RECEPTORS, CHEMOKINE;

EID: 78650173034     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.07.019     Document Type: Review

References (166)

1. Ransohoff R.M., Kivisakk P., Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat. Rev. Immunol. 2003, 3:569-581.
2. Abbott N.J., Ronnback L., Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 2006, 7:41-53.
3. Johanson C.E., Duncan J.A., Klinge P.M., Brinker T., Stopa E.G., Silverberg G.D. Multiplicity of cerebrospinal fluid functions: new challenges in health and disease. Cerebrospinal Fluid Res. 2008, 5:10.
4. Ge S., Song L., Pachter J.S. Where is the blood-brain barrier really?. J. Neurosci. Res. 2005, 79:421-427.
5. Chi J.T., Chang H.Y., Haraldsen G., Jahnsen F.L., Troyanskaya O.G., Chang D.S., Wang Z., Rockson S.G., van de Rijn M., Botstein D., Brown P.O. Endothelial cell diversity revealed by global expression profiling. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:10623-10628.
6. Podgrabinska S., Braun P., Velasco P., Kloos B., Pepper M.S., Skobe M. Molecular characterization of lymphatic endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:16069-16074.
7. St Croix B., Rago C., Velculescu V., Traverso G., Romans K.E., Montgomery E., Lal A., Riggins G.J., Lengauer C., Vogelstein B., Kinzler K.W. Genes expressed in human tumor endothelium. Science 2000, 289:1197-1202.
8. Virgintino D., Robertson D., Errede M., Benagiano V., Girolamo F., Maiorano E., Roncali L., Bertossi M. Expression of P-glycoprotein in human cerebral cortex microvessels. J. Histochem. Cytochem. 2002, 50:1671-1676.
9. Simionescu M., Simionescu N., Palade G.E. Segmental differentiations of cell junctions in the vascular endothelium. Arteries and veins. J. Cell Biol. 1976, 68:705-723.
10. Simionescu M., Simionescu N., Palade G.E. Segmental differentiations of cell junctions in the vascular endothelium. The microvasculature. J. Cell Biol. 1975, 67:863-885.
11. Nagy Z., Peters H., Huttner I. Fracture faces of cell junctions in cerebral endothelium during normal and hyperosmotic conditions. Lab. Invest. 1984, 50:313-322.
12. Butt A.M., Jones H.C. Effect of histamine and antagonists on electrical resistance across the blood-brain barrier in rat brain-surface microvessels. Brain Res. 1992, 569:100-105.
13. Butt A.M., Jones H.C., Abbott N.J. Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study. J. Physiol. 1990, 429:47-62.
14. Claude P. Morphological factors influencing transepithelial permeability: a model for the resistance of the zonula occludens. J. Membr. Biol. 1978, 39:219-232.
15. Claude P., Goodenough D.A. Fracture faces of zonulae occludentes from "tight" and "leaky" epithelia. J. Cell Biol. 1973, 58:390-400.
16. Allt G., Lawrenson J.G. Is the pial microvessel a good model for blood-brain barrier studies?. Brain Res. Brain Res. Rev. 1997, 24:67-76.
17. Kivisakk P., Mahad D.J., Callahan M.K., Trebst C., Tucky B., Wei T., Wu L., Baekkevold E.S., Lassmann H., Staugaitis S.M., Campbell J.J., Ransohoff R.M. Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8389-8394.
18. Kerfoot S.M., Kubes P. Overlapping roles of P-selectin and alpha 4 integrin to recruit leukocytes to the central nervous system in experimental autoimmune encephalomyelitis. J. Immunol. 2002, 169:1000-1006.
19. Battistini L., Piccio L., Rossi B., Bach S., Galgani S., Gasperini C., Ottoboni L., Ciabini D., Caramia M.D., Bernardi G., Laudanna C., Scarpini E., McEver R.P., Butcher E.C., Borsellino G., Constantin G. CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1. Blood 2003, 101:4775-4782.
20. Vajkoczy P., Laschinger M., Engelhardt B. Alpha4-integrin-VCAM-1 binding mediates G protein-independent capture of encephalitogenic T cell blasts to CNS white matter microvessels. J. Clin. Invest. 2001, 108:557-565.
21. McCandless E.E., Piccio L., Woerner B.M., Schmidt R.E., Rubin J.B., Cross A.H., Klein R.S. Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis. Am. J. Pathol. 2008, 172:799-808.
22. McCandless E.E., Wang Q., Woerner B.M., Harper J.M., Klein R.S. CXCL12 limits inflammation by localizing mononuclear infiltrates to the perivascular space during experimental autoimmune encephalomyelitis. J. Immunol. 2006, 177:8053-8064.
23. Galea I., Bechmann I., Perry V.H. What is immune privilege (not)?. Trends Immunol. 2007, 28:12-18.
24. Carson M.J., Doose J.M., Melchior B., Schmid C.D., Ploix C.C. CNS immune privilege: hiding in plain sight. Immunol. Rev. 2006, 213:48-65.
25. Matyszak M.K., Perry V.H. Demyelination in the central nervous system following a delayed-type hypersensitivity response to bacillus Calmette-Guerin. Neuroscience 1995, 64:967-977.
26. Stevenson P.G., Hawke S., Sloan D.J., Bangham C.R. The immunogenicity of intracerebral virus infection depends on anatomical site. J. Virol. 1997, 71:145-151.
27. Byrnes A.P., MacLaren R.E., Charlton H.M. Immunological instability of persistent adenovirus vectors in the brain: peripheral exposure to vector leads to renewed inflammation, reduced gene expression, and demyelination. J. Neurosci. 1996, 16:3045-3055.
28. Lowenstein P.R. Immunology of viral-vector-mediated gene transfer into the brain: an evolutionary and developmental perspective. Trends Immunol. 2002, 23:23-30.
29. Matyszak M.K., Perry V.H. A comparison of leucocyte responses to heat-killed bacillus Calmette-Guerin in different CNS compartments. Neuropathol. Appl. Neurobiol. 1996, 22:44-53.
30. Perry V.H. A revised view of the central nervous system microenvironment and major histocompatibility complex class II antigen presentation. J. Neuroimmunol. 1998, 90:113-121.
31. Mason D.W., Charlton H.M., Jones A.J., Lavy C.B., Puklavec M., Simmonds S.J. The fate of allogeneic and xenogeneic neuronal tissue transplanted into the third ventricle of rodents. Neuroscience 1986, 19:685-694.
32. Magliozzi R., Howell O., Vora A., Serafini B., Nicholas R., Puopolo M., Reynolds R., Aloisi F. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007, 130:1089-1104.
33. Serafini B., Rosicarelli B., Magliozzi R., Stigliano E., Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004, 14:164-174.
34. Kivisakk P., Imitola J., Rasmussen S., Elyaman W., Zhu B., Ransohoff R.M., Khoury S.J. Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis. Ann. Neurol. 2009, 65:457-469.
35. Goldsmith H.L., Spain S. Margination of leukocytes in blood flow through small tubes. Microvasc. Res. 1984, 27:204-222.
36. Ley K. Molecular mechanisms of leukocyte recruitment in the inflammatory process. Cardiovasc. Res. 1996, 32:733-742.
37. Schmid-Schonbein G.W., Usami S., Skalak R., Chien S. The interaction of leukocytes and erythrocytes in capillary and postcapillary vessels. Microvasc. Res. 1980, 19:45-70.
38. Nobis U., Pries A.R., Cokelet G.R., Gaehtgens P. Radial distribution of white cells during blood flow in small tubes. Microvasc. Res. 1985, 29:295-304.
39. Ley K., Laudanna C., Cybulsky M.I., Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 2007, 7:678-689.
40. Johnston B., Butcher E.C. Chemokines in rapid leukocyte adhesion triggering and migration. Semin. Immunol. 2002, 14:83-92.
41. Alon R., Feigelson S. From rolling to arrest on blood vessels: leukocyte tap dancing on endothelial integrin ligands and chemokines at sub-second contacts. Semin. Immunol. 2002, 14:93-104.
42. Cinamon G., Grabovsky V., Winter E., Franitza S., Feigelson S., Shamri R., Dwir O., Alon R. Novel chemokine functions in lymphocyte migration through vascular endothelium under shear flow. J. Leukoc. Biol. 2001, 69:860-866.
43. Adamson P., Wilbourn B., Etienne-Manneville S., Calder V., Beraud E., Milligan G., Couraud P.O., Greenwood J. Lymphocyte trafficking through the blood-brain barrier is dependent on endothelial cell heterotrimeric G-protein signaling. FASEB J. 2002, 16:1185-1194.
44. Proudfoot A.E. The biological relevance of chemokine-proteoglycan interactions. Biochem. Soc. Trans. 2006, 34:422-426.
45. Parish C.R. The role of heparan sulphate in inflammation. Nat. Rev. Immunol. 2006, 6:633-643.
46. Carman C.V., Springer T.A. Trans-cellular migration: cell-cell contacts get intimate. Curr. Opin. Cell Biol. 2008, 20:533-540.
47. Vestweber D. Adhesion and signaling molecules controlling the transmigration of leukocytes through endothelium. Immunol. Rev. 2007, 218:178-196.
48. Liao F., Ali J., Greene T., Muller W.A. Soluble domain 1 of platelet-endothelial cell adhesion molecule (PECAM) is sufficient to block transendothelial migration in vitro and in vivo. J. Exp. Med. 1997, 185:1349-1357.
49. Liao F., Huynh H.K., Eiroa A., Greene T., Polizzi E., Muller W.A. Migration of monocytes across endothelium and passage through extracellular matrix involve separate molecular domains of PECAM-1. J. Exp. Med. 1995, 182:1337-1343.
50. Duncan G.S., Andrew D.P., Takimoto H., Kaufman S.A., Yoshida H., Spellberg J., Luis de la Pompa J., Elia A., Wakeham A., Karan-Tamir B., Muller W.A., Senaldi G., Zukowski M.M., Mak T.W. Genetic evidence for functional redundancy of Platelet/Endothelial cell adhesion molecule-1 (PECAM-1): CD31-deficient mice reveal PECAM-1-dependent and PECAM-1-independent functions. J. Immunol. 1999, 162:3022-3030.
51. Wakelin M.W., Sanz M.J., Dewar A., Albelda S.M., Larkin S.W., Boughton-Smith N., Williams T.J., Nourshargh S. An anti-platelet-endothelial cell adhesion molecule-1 antibody inhibits leukocyte extravasation from mesenteric microvessels in vivo by blocking the passage through the basement membrane. J. Exp. Med. 1996, 184:229-239.
52. Schenkel A.R., Mamdouh Z., Chen X., Liebman R.M., Muller W.A. CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat. Immunol. 2002, 3:143-150.
53. Bixel G., Kloep S., Butz S., Petri B., Engelhardt B., Vestweber D. Mouse CD99 participates in T-cell recruitment into inflamed skin. Blood 2004, 104:3205-3213.
54. Engelhardt B., Wolburg H. Mini-review: Transendothelial migration of leukocytes: through the front door or around the side of the house?. Eur. J. Immunol. 2004, 34:2955-2963.
55. Raine C.S., Cannella B., Duijvestijn A.M., Cross A.H. Homing to central nervous system vasculature by antigen-specific lymphocytes. II. Lymphocyte/endothelial cell adhesion during the initial stages of autoimmune demyelination. Lab. Invest. 1990, 63:476-489.
56. Wolburg H., Wolburg-Buchholz K., Engelhardt B. Diapedesis of mononuclear cells across cerebral venules during experimental autoimmune encephalomyelitis leaves tight junctions intact. Acta Neuropathol. 2005, 109:181-190.
57. Kniesel U., Risau W., Wolburg H. Development of blood-brain barrier tight junctions in the rat cortex. Brain Res. Dev. Brain Res. 1996, 96:229-240.
58. Owens T., Bechmann I., Engelhardt B. Perivascular spaces and the two steps to neuroinflammation. J. Neuropathol. Exp. Neurol. 2008, 67:1113-1121.
59. Bartholomaus I., Kawakami N., Odoardi F., Schlager C., Miljkovic D., Ellwart J.W., Klinkert W.E., Flugel-Koch C., Issekutz T.B., Wekerle H., Flugel A. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 2009, 462:94-98.
60. Ransohoff R.M. Immunology: in the beginning. Nature 2009, 462:41-42.
61. Zachariae C.O. Chemotactic cytokines and inflammation. Biological properties of the lymphocyte and monocyte chemotactic factors ELCF, MCAF and IL-8. Acta Derm. Venereol. Suppl. (Stockh.) 1993, 181:1-37.
62. Rot A. Neutrophil attractant/activation protein-1 (interleukin-8) induces in vitro neutrophil migration by haptotactic mechanism. Eur. J. Immunol. 1993, 23:303-306.
63. Johnson Z., Kosco-Vilbois M.H., Herren S., Cirillo R., Muzio V., Zaratin P., Carbonatto M., Mack M., Smailbegovic A., Rose M., Lever R., Page C., Wells T.N., Proudfoot A.E. Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system. J. Immunol. 2004, 173:5776-5785.
64. Peled A., Grabovsky V., Habler L., Sandbank J., Arenzana-Seisdedos F., Petit I., Ben-Hur H., Lapidot T., Alon R. The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow. J. Clin. Invest. 1999, 104:1199-1211.
65. Cinamon G., Shinder V., Alon R. Shear forces promote lymphocyte migration across vascular endothelium bearing apical chemokines. Nat. Immunol. 2001, 2:515-522.
66. Schreiber T.H., Shinder V., Cain D.W., Alon R., Sackstein R. Shear flow-dependent integration of apical and subendothelial chemokines in T-cell transmigration: implications for locomotion and the multistep paradigm. Blood 2007, 109:1381-1386.
67. Handel T.M., Johnson Z., Crown S.E., Lau E.K., Proudfoot A.E. Regulation of protein function by glycosaminoglycans-as exemplified by chemokines. Annu. Rev. Biochem. 2005, 74:385-410.
68. Spillmann D., Witt D., Lindahl U. Defining the interleukin-8-binding domain of heparan sulfate. J. Biol. Chem. 1998, 273:15487-15493.
69. Amara A., Lorthioir O., Valenzuela A., Magerus A., Thelen M., Montes M., Virelizier J.L., Delepierre M., Baleux F., Lortat-Jacob H., Arenzana-Seisdedos F. Stromal cell-derived factor-1alpha associates with heparan sulfates through the first beta-strand of the chemokine. J. Biol. Chem. 1999, 274:23916-23925.
70. Martin L., Blanpain C., Garnier P., Wittamer V., Parmentier M., Vita C. Structural and functional analysis of the RANTES-glycosaminoglycans interactions. Biochemistry 2001, 40:6303-6318.
71. Hoogewerf A.J., Kuschert G.S., Proudfoot A.E., Borlat F., Clark-Lewis I., Power C.A., Wells T.N. Glycosaminoglycans mediate cell surface oligomerization of chemokines. Biochemistry 1997, 36:13570-13578.
72. Ranjbaran H., Wang Y., Manes T.D., Yakimov A.O., Akhtar S., Kluger M.S., Pober J.S., Tellides G. Heparin displaces interferon-gamma-inducible chemokines (IP-10, I-TAC, and Mig) sequestered in the vasculature and inhibits the transendothelial migration and arterial recruitment of T cells. Circulation 2006, 114:1293-1300.
73. Proudfoot A.E., Handel T.M., Johnson Z., Lau E.K., LiWang P., Clark-Lewis I., Borlat F., Wells T.N., Kosco-Vilbois M.H. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:1885-1890.
74. Ali S., Robertson H., Wain J.H., Isaacs J.D., Malik G., Kirby J.A. A non-glycosaminoglycan-binding variant of CC chemokine ligand 7 (monocyte chemoattractant protein-3) antagonizes chemokine-mediated inflammation. J. Immunol. 2005, 175:1257-1266.
75. Peterson F.C., Elgin E.S., Nelson T.J., Zhang F., Hoeger T.J., Linhardt R.J., Volkman B.F. Identification and characterization of a glycosaminoglycan recognition element of the C chemokine lymphotactin. J. Biol. Chem. 2004, 279:12598-12604.
76. Johnson Z., Proudfoot A.E., Handel T.M. Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention. Cytokine Growth Factor Rev. 2005, 16:625-636.
77. Agace W.W. Tissue-tropic effector T cells: generation and targeting opportunities. Nat. Rev. Immunol. 2006, 6:682-692.
78. Wang L., Fuster M., Sriramarao P., Esko J.D. Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat. Immunol. 2005, 6:902-910.
79. Shaik S.S., Soltau T.D., Chaturvedi G., Totapally B., Hagood J.S., Andrews W.W., Athar M., Voitenok N.N., Killingsworth C.R., Patel R.P., Fallon M.B., Maheshwari A. Low intensity shear stress increases endothelial ELR+ CXC chemokine production via a focal adhesion kinase-p38{beta} MAPK-NF-{kappa}B pathway. J. Biol. Chem. 2009, 284:5945-5955.
80. Hol J., Kuchler A.M., Johansen F.E., Dalhus B., Haraldsen G., Oynebraten I. Molecular requirements for sorting of the chemokine IL-8/CXCL8 to endothelial Weibel-Palade bodies. J. Biol. Chem. 2009, 284:23532-23539.
81. Utgaard J.O., Jahnsen F.L., Bakka A., Brandtzaeg P., Haraldsen G. Rapid secretion of prestored interleukin 8 from Weibel-Palade bodies of microvascular endothelial cells. J. Exp. Med. 1998, 188:1751-1756.
82. Wolff B., Burns A.R., Middleton J., Rot A. Endothelial cell "memory" of inflammatory stimulation: human venular endothelial cells store interleukin 8 in Weibel-Palade bodies. J. Exp. Med. 1998, 188:1757-1762.
83. Barkalow F.J., Goodman M.J., Gerritsen M.E., Mayadas T.N. Brain endothelium lack one of two pathways of P-selectin-mediated neutrophil adhesion. Blood 1996, 88:4585-4593.
84. Barkalow F.J., Goodman M.J., Mayadas T.N. Cultured murine cerebral microvascular endothelial cells contain von Willebrand factor-positive Weibel-Palade bodies and support rapid cytokine-induced neutrophil adhesion. Microcirculation 1996, 3:19-28.
85. Cardona A.E., Li M., Liu L., Savarin C., Ransohoff R.M. Chemokines in and out of the central nervous system: much more than chemotaxis and inflammation. J. Leukoc. Biol. 2008, 84:587-594.
86. Panzer U., Steinmetz O.M., Reinking R.R., Meyer T.N., Fehr S., Schneider A., Zahner G., Wolf G., Helmchen U., Schaerli P., Stahl R.A., Thaiss F. Compartment-specific expression and function of the chemokine IP-10/CXCL10 in a model of renal endothelial microvascular injury. J. Am. Soc. Nephrol. 2006, 17:454-464.
87. Kieseier B.C., Tani M., Mahad D., Oka N., Ho T., Woodroofe N., Griffin J.W., Toyka K.V., Ransohoff R.M., Hartung H.P. Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain 2002, 125:823-834.
88. Reutershan J., Morris M.A., Burcin T.L., Smith D.F., Chang D., Saprito M.S., Ley K. Critical role of endothelial CXCR2 in LPS-induced neutrophil migration into the lung. J. Clin. Invest. 2006, 116:695-702.
89. Reutershan J., Harry B., Chang D., Bagby G.J., Ley K. DARC on RBC limits lung injury by balancing compartmental distribution of CXC chemokines. Eur. J. Immunol. 2009, 39:1597-1607.
90. Tsou C.L., Haskell C.A., Charo I.F. Tumor necrosis factor-alpha-converting enzyme mediates the inducible cleavage of fractalkine. J. Biol. Chem. 2001, 276:44622-44626.
91. Patel D.D., Koopmann W., Imai T., Whichard L.P., Yoshie O., Krangel M.S. Chemokines have diverse abilities to form solid phase gradients. Clin. Immunol. 2001, 99:43-52.
92. Fong A.M., Robinson L.A., Steeber D.A., Tedder T.F., Yoshie O., Imai T., Patel D.D. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J. Exp. Med. 1998, 188:1413-1419.
93. Umehara H., Imai T. Role of fractalkine in leukocyte adhesion and migration and in vascular injury. Drug News Perspect. 2001, 14:460-464.
94. Harrison J.K., Jiang Y., Chen S., Xia Y., Maciejewski D., McNamara R.K., Streit W.J., Salafranca M.N., Adhikari S., Thompson D.A., Botti P., Bacon K.B., Feng L. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:10896-10901.
95. Sunnemark D., Eltayeb S., Nilsson M., Wallstrom E., Lassmann H., Olsson T., Berg A.L., Ericsson-Dahlstrand A. CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin. J. Neuroinflammation 2005, 2:17.
96. Huang D., Shi F.D., Jung S., Pien G.C., Wang J., Salazar-Mather T.P., He T.T., Weaver J.T., Ljunggren H.G., Biron C.A., Littman D.R., Ransohoff R.M. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J. 2006, 20:896-905.
97. Andjelkovic A.V., Spencer D.D., Pachter J.S. Visualization of chemokine binding sites on human brain microvessels. J. Cell Biol. 1999, 145:403-412.
98. Dimitrijevic O.B., Stamatovic S.M., Keep R.F., Andjelkovic A.V. Effects of the chemokine CCL2 on blood-brain barrier permeability during ischemia-reperfusion injury. J. Cereb. Blood Flow Metab. 2006, 26:797-810.
99. Stamatovic S.M., Keep R.F., Kunkel S.L., Andjelkovic A.V. Potential role of MCP-1 in endothelial cell tight junction 'opening': signaling via Rho and Rho kinase. J. Cell Sci. 2003, 116:4615-4628.
100. Quandt J., Dorovini-Zis K. The beta chemokines CCL4 and CCL5 enhance adhesion of specific CD4+ T cell subsets to human brain endothelial cells. J. Neuropathol. Exp. Neurol. 2004, 63:350-362.
101. Szczucinski A., Losy J. Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Acta Neurol. Scand. 2007, 115:137-146.
102. Izikson L., Klein R.S., Charo I.F., Weiner H.L., Luster A.D. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J. Exp. Med. 2000, 192:1075-1080.
103. Izikson L., Klein R.S., Luster A.D., Weiner H.L. Targeting monocyte recruitment in CNS autoimmune disease. Clin. Immunol. 2002, 103:125-131.
104. Fife B.T., Huffnagle G.B., Kuziel W.A., Karpus W.J. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J. Exp. Med. 2000, 192:899-905.
105. Fife B.T., Paniagua M.C., Lukacs N.W., Kunkel S.L., Karpus W.J. Selective CC chemokine receptor expression by central nervous system-infiltrating encephalitogenic T cells during experimental autoimmune encephalomyelitis. J. Neurosci. Res. 2001, 66:705-714.
106. Mahad D., Callahan M.K., Williams K.A., Ubogu E.E., Kivisakk P., Tucky B., Kidd G., Kingsbury G.A., Chang A., Fox R.J., Mack M., Sniderman M.B., Ravid R., Staugaitis S.M., Stins M.F., Ransohoff R.M. Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain 2006, 129:212-223.
107. Mahad D.J., Ransohoff R.M. The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin. Immunol. 2003, 15:23-32.
108. Sorensen T.L., Ransohoff R.M., Strieter R.M., Sellebjerg F. Chemokine CCL2 and chemokine receptor CCR2 in early active multiple sclerosis. Eur. J. Neurol. 2004, 11:445-449.
109. Gaupp S., Pitt D., Kuziel W.A., Cannella B., Raine C.S. Experimental autoimmune encephalomyelitis (EAE) in CCR2(-/-) mice: susceptibility in multiple strains. Am. J. Pathol. 2003, 162:139-150.
110. Huang D.R., Wang J., Kivisakk P., Rollins B.J., Ransohoff R.M. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J. Exp. Med. 2001, 193:713-726.
111. Bennetts B.H., Teutsch S.M., Buhler M.M., Heard R.N., Stewart G.J. The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum. Immunol. 1997, 58:52-59.
112. Tran E.H., Kuziel W.A., Owens T. Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein-1alpha or its CCR5 receptor. Eur. J. Immunol. 2000, 30:1410-1415.
113. Bachmann M.F., Kopf M., Marsland B.J. Chemokines: more than just road signs. Nat. Rev. Immunol. 2006, 6:159-164.
114. Bromley S.K., Mempel T.R., Luster A.D. Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat. Immunol. 2008, 9:970-980.
115. Alt C., Laschinger M., Engelhardt B. Functional expression of the lymphoid chemokines CCL19 (ELC) and CCL 21 (SLC) at the blood-brain barrier suggests their involvement in G-protein-dependent lymphocyte recruitment into the central nervous system during experimental autoimmune encephalomyelitis. Eur. J. Immunol. 2002, 32:2133-2144.
116. Columba-Cabezas S., Serafini B., Ambrosini E., Aloisi F. Lymphoid chemokines CCL19 and CCL21 are expressed in the central nervous system during experimental autoimmune encephalomyelitis: implications for the maintenance of chronic neuroinflammation. Brain Pathol. 2003, 13:38-51.
117. Chen S.C., Leach M.W., Chen Y., Cai X.Y., Sullivan L., Wiekowski M., Dovey-Hartman B.J., Zlotnik A., Lira S.A. Central nervous system inflammation and neurological disease in transgenic mice expressing the CC chemokine CCL21 in oligodendrocytes. J. Immunol. 2002, 168:1009-1017.
118. Biber K., Sauter A., Brouwer N., Copray S.C., Boddeke H.W. Ischemia-induced neuronal expression of the microglia attracting chemokine Secondary Lymphoid-tissue Chemokine (SLC). Glia 2001, 34:121-133.
119. Dijkstra I.M., Hulshof S., van der Valk P., Boddeke H.W., Biber K. Cutting edge: activity of human adult microglia in response to CC chemokine ligand 21. J. Immunol. 2004, 172:2744-2747.
120. Rappert A., Biber K., Nolte C., Lipp M., Schubel A., Lu B., Gerard N.P., Gerard C., Boddeke H.W., Kettenmann H. Secondary lymphoid tissue chemokine (CCL21) activates CXCR3 to trigger a Cl- current and chemotaxis in murine microglia. J. Immunol. 2002, 168:3221-3226.
121. Weering H.R., Jong A.P., Haas A.H., Biber K.P., Boddeke H.W. CCL21-induced calcium transients and proliferation in primary mouse astrocytes: CXCR3-dependent and independent responses. Brain Behav. Immun. 2009, 24:768-775.
122. Kivisakk P., Mahad D.J., Callahan M.K., Sikora K., Trebst C., Tucky B., Wujek J., Ravid R., Staugaitis S.M., Lassmann H., Ransohoff R.M. Expression of CCR7 in multiple sclerosis: implications for CNS immunity. Ann. Neurol. 2004, 55:627-638.
123. Buonamici S., Trimarchi T., Ruocco M.G., Reavie L., Cathelin S., Mar B.G., Klinakis A., Lukyanov Y., Tseng J.C., Sen F., Gehrie E., Li M., Newcomb E., Zavadil J., Meruelo D., Lipp M., Ibrahim S., Efstratiadis A., Zagzag D., Bromberg J.S., Dustin M.L., Aifantis I. CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature 2009, 459:1000-1004.
124. Reboldi A., Coisne C., Baumjohann D., Benvenuto F., Bottinelli D., Lira S., Uccelli A., Lanzavecchia A., Engelhardt B., Sallusto F. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat. Immunol. 2009, 10:514-523.
125. Krumbholz M., Theil D., Steinmeyer F., Cepok S., Hemmer B., Hofbauer M., Farina C., Derfuss T., Junker A., Arzberger T., Sinicina I., Hartle C., Newcombe J., Hohlfeld R., Meinl E. CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions. J. Neuroimmunol. 2007, 190:72-79.
126. Bleul C.C., Fuhlbrigge R.C., Casasnovas J.M., Aiuti A., Springer T.A. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J. Exp. Med. 1996, 184:1101-1109.
127. Stumm R.K., Rummel J., Junker V., Culmsee C., Pfeiffer M., Krieglstein J., Hollt V., Schulz S. A dual role for the SDF-1/CXCR4 chemokine receptor system in adult brain: isoform-selective regulation of SDF-1 expression modulates CXCR4-dependent neuronal plasticity and cerebral leukocyte recruitment after focal ischemia. J. Neurosci. 2002, 22:5865-5878.
128. Li M., Ransohoff R.M. Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology. Prog. Neurobiol. 2008, 84:116-131.
129. Klein R.S., Rubin J.B. Immune and nervous system CXCL12 and CXCR4: parallel roles in patterning and plasticity. Trends Immunol. 2004, 25:306-314.
130. van der Meer P., Ulrich A.M., Gonzalez-Scarano F., Lavi E. Immunohistochemical analysis of CCR2, CCR3, CCR5, and CXCR4 in the human brain: potential mechanisms for HIV dementia. Exp. Mol. Pathol. 2000, 69:192-201.
131. Jazin E.E., Soderstrom S., Ebendal T., Larhammar D. Embryonic expression of the mRNA for the rat homologue of the fusin/CXCR-4 HIV-1 co-receptor. J. Neuroimmunol. 1997, 79:148-154.
132. McGrath K.E., Koniski A.D., Maltby K.M., McGann J.K., Palis J. Embryonic expression and function of the chemokine SDF-1 and its receptor, CXCR4. Dev. Biol. 1999, 213:442-456.
133. Krumbholz M., Theil D., Cepok S., Hemmer B., Kivisakk P., Ransohoff R.M., Hofbauer M., Farina C., Derfuss T., Hartle C., Newcombe J., Hohlfeld R., Meinl E. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 2006, 129:200-211.
134. McCandless E.E., Zhang B., Diamond M.S., Klein R.S. CXCR4 antagonism increases T cell trafficking in the central nervous system and improves survival from West Nile virus encephalitis. Proc. Natl. Acad. Sci. U.S.A 2008, 105:11270-11275.
135. McCandless E.E., Budde M., Lees J.R., Dorsey D., Lyng E., Klein R.S. IL-1R signaling within the central nervous system regulates CXCL12 expression at the blood-brain barrier and disease severity during experimental autoimmune encephalomyelitis. J. Immunol. 2009, 183:613-620.
136. Balabanian K., Lagane B., Infantino S., Chow K.Y., Harriague J., Moepps B., Arenzana-Seisdedos F., Thelen M., Bachelerie F. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J. Biol. Chem. 2005, 280:35760-35766.
137. Burns J.M., Summers B.C., Wang Y., Melikian A., Berahovich R., Miao Z., Penfold M.E., Sunshine M.J., Littman D.R., Kuo C.J., Wei K., McMaster B.E., Wright K., Howard M.C., Schall T.J. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med. 2006, 203:2201-2213.
138. Mazzinghi B., Ronconi E., Lazzeri E., Sagrinati C., Ballerini L., Angelotti M.L., Parente E., Mancina R., Netti G.S., Becherucci F., Gacci M., Carini M., Gesualdo L., Rotondi M., Maggi E., Lasagni L., Serio M., Romagnani S., Romagnani P. Essential but differential role for CXCR4 and CXCR7 in the therapeutic homing of human renal progenitor cells. J. Exp. Med. 2008, 205:479-490.
139. Sierro F., Biben C., Martinez-Munoz L., Mellado M., Ransohoff R.M., Li M., Woehl B., Leung H., Groom J., Batten M., Harvey R.P., Martinez A.C., Mackay C.R., Mackay F. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:14759-14764.
140. Wang J., Shiozawa Y., Wang J., Wang Y., Jung Y., Pienta K.J., Mehra R., Loberg R., Taichman R.S. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J. Biol. Chem. 2008, 283:4283-4294.
141. Proost P., Mortier A., Loos T., Vandercappellen J., Gouwy M., Ronsse I., Schutyser E., Put W., Parmentier M., Struyf S., Van Damme J. Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. Blood 2007, 110:37-44.
142. Yoshida D., Nomura R., Teramoto A. Signaling pathway mediated by CXCR7, an alternative chemokine receptor for stromal-cell derived factor-1alpha, in AtT20 mouse ACTH-secreting pituitary adenoma cells. J. Neuroendocrinol. 2009, 21:481-488.
143. Hartmann T.N., Grabovsky V., Pasvolsky R., Shulman Z., Buss E.C., Spiegel A., Nagler A., Lapidot T., Thelen M., Alon R. A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells. J. Leukoc. Biol. 2008, 84:1130-1140.
144. Boldajipour B., Mahabaleshwar H., Kardash E., Reichman-Fried M., Blaser H., Minina S., Wilson D., Xu Q., Raz E. Control of chemokine-guided cell migration by ligand sequestration. Cell 2008, 132:463-473.
145. Mahabaleshwar H., Boldajipour B., Raz E. Killing the messenger: the role of CXCR7 in regulating primordial germ cell migration. Cell Adh. Migr. 2008, 2:69-70.
146. Schonemeier B., Kolodziej A., Schulz S., Jacobs S., Hoellt V., Stumm R. Regional and cellular localization of the CXCl12/SDF-1 chemokine receptor CXCR7 in the developing and adult rat brain. J. Comp. Neurol. 2008, 510:207-220.
147. Schonemeier B., Schulz S., Hoellt V., Stumm R. Enhanced expression of the CXCl12/SDF-1 chemokine receptor CXCR7 after cerebral ischemia in the rat brain. J. Neuroimmunol. 2008, 198:39-45.
148. Miao Z., Luker K.E., Summers B.C., Berahovich R., Bhojani M.S., Rehemtulla A., Kleer C.G., Essner J.J., Nasevicius A., Luker G.D., Howard M.C., Schall T.J. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:15735-15740.
149. Zabel B.A., Wang Y., Lewen S., Berahovich R.D., Penfold M.E., Zhang P., Powers J., Summers B.C., Miao Z., Zhao B., Jalili A., Janowska-Wieczorek A., Jaen J.C., Schall T.J. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J. Immunol. 2009, 183:3204-3211.
150. Maghazachi A.A. G protein-coupled receptors in natural killer cells. J. Leukoc. Biol. 2003, 74:16-24.
151. Dagkalis A., Wallace C., Hing B., Liversidge J., Crane I.J. CX3CR1-deficiency is associated with increased severity of disease in experimental autoimmune uveitis. Immunology 2009, 128:25-33.
152. Tran E.H., Prince E.N., Owens T. IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines. J. Immunol. 2000, 164:2759-2768.
153. Carlson T., Kroenke M., Rao P., Lane T.E., Segal B. The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease. J. Exp. Med. 2008, 205:811-823.
154. Shaftel S.S., Carlson T.J., Olschowka J.A., Kyrkanides S., Matousek S.B., O'Banion M.K. Chronic interleukin-1beta expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood brain barrier permeability without overt neurodegeneration. J. Neurosci. 2007, 27:9301-9309.
155. Hanisch U.K. Microglia as a source and target of cytokines. Glia 2002, 40:140-155.
156. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996, 19:312-318.
157. Gonzalez-Scarano F., Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu. Rev. Neurosci. 1999, 22:219-240.
158. Li Y.Q., Chen P., Jain V., Reilly R.M., Wong C.S. Early radiation-induced endothelial cell loss and blood-spinal cord barrier breakdown in the rat spinal cord. Radiat. Res. 2004, 161:143-152.
159. Diserbo M., Agin A., Lamproglou I., Mauris J., Staali F., Multon E., Amourette C. Blood-brain barrier permeability after gamma whole-body irradiation: an in vivo microdialysis study. Can. J. Physiol. Pharmacol. 2002, 80:670-678.
160. Ajami B., Bennett J.L., Krieger C., Tetzlaff W., Rossi F.M. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat. Neurosci. 2007, 10:1538-1543.
161. Hess D.C., Abe T., Hill W.D., Studdard A.M., Carothers J., Masuya M., Fleming P.A., Drake C.J., Ogawa M. Hematopoietic origin of microglial and perivascular cells in brain. Exp. Neurol. 2004, 186:134-144.
162. Simard A.R., Rivest S. Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia. FASEB J. 2004, 18:998-1000.
163. Priller J., Flugel A., Wehner T., Boentert M., Haas C.A., Prinz M., Fernandez-Klett F., Prass K., Bechmann I., de Boer B.A., Frotscher M., Kreutzberg G.W., Persons D.A., Dirnagl U. Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nat. Med. 2001, 7:1356-1361.
164. Kennedy D.W., Abkowitz J.L. Kinetics of central nervous system microglial and macrophage engraftment: analysis using a transgenic bone marrow transplantation model. Blood 1997, 90:986-993.
165. Flugel A., Bradl M., Kreutzberg G.W., Graeber M.B. Transformation of donor-derived bone marrow precursors into host microglia during autoimmune CNS inflammation and during the retrograde response to axotomy. J. Neurosci. Res. 2001, 66:74-82.
166. Mildner A., Schmidt H., Nitsche M., Merkler D., Hanisch U.K., Mack M., Heikenwalder M., Bruck W., Priller J., Prinz M. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat. Neurosci. 2007, 10:1544-1553.